重组人干扰素-α1b 在体外抑制 SARS-CoV-2 的效果优于干扰素-α2b。
Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro.
机构信息
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, China.
出版信息
Virol Sin. 2022 Apr;37(2):295-298. doi: 10.1016/j.virs.2022.01.031. Epub 2022 Jan 25.
• A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on qPCR, TCID, and immunofluorescence. • A significant antiviral effect of rHuIFN-α1b was shown in Vero and Calu-3 cells. • rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.
• 建立了基于 qPCR、TCID 和免疫荧光的抗 SARS-CoV-2 药物综合评价方法。
• rHuIFN-α1b 在 Vero 和 Calu-3 细胞中表现出显著的抗病毒作用。
• rHuIFN-α1b 在抗 COVID-19 治疗应用中具有良好的潜力。
Zotero 插件